This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pileri, S. A. Articles by Falini, B. Search for Related Content PubMed PubMed Citation Articles by Pileri, S. A. Articles by Falini, B.

American Journal of Pathology, Vol 150, 1207-1211, Copyright © 1997 by American Society for Investigative Pathology

REGULAR ARTICLES

Frequent expression of the NPM-ALK chimeric fusion protein in anaplastic large-cell lymphoma, lympho-histiocytic type

SA Pileri, K Pulford, S Mori, DY Mason, E Sabattini, G Roncador, M Piccioli, C Ceccarelli, PP Piccaluga, D Santini, O Leone, H Stein and B Falini
Service of Pathologic Anatomy and Hematopathology Section, Bologna University, Italy.

The revised European-American lymphoma classification recognizes a subtype of anaplastic large-cell lymphoma (ALCL), termed lympho- histiocytic because of its peculiar cytological composition. As in the case of classical ALCL, this tumor usually occurs in young patients and shows an excellent response to chemotherapy, but some authors have suggested that in reality this is a nonanaplastic T-cell lymphoma rich in histiocytes. In this paper, we show that three of five cases of lympho-histiocytic ALCL stain with anti-ALK antibodies and can therefore be presumed to express the chimeric NPM/ALK protein secondary to (2;5) translocation. These findings further support the inclusion of this as a type of ALCL and not among the nonanaplastic peripheral T- cell lymphomas. Furthermore, they indicate that staining for ALK proteins is a powerful tool for the diagnosis of lympho-histiocytic ALCL, the recognition of which may be difficult on morphological grounds.

This article has been cited by other articles:

				J. L. Kutok and J. C. Aster Molecular Biology of Anaplastic Lymphoma Kinase-Positive Anaplastic Large-Cell Lymphoma J. Clin. Oncol., September 1, 2002; 20(17): 3691 - 3702. [Abstract] [Full Text] [PDF]

				S A Pileri, S Ascani, L Leoncini, E Sabattini, P L Zinzani, P P Piccaluga, A Pileri Jr, M Giunti, B Falini, G B Bolis, et al. Hodgkin's lymphoma: the pathologist's viewpoint J. Clin. Pathol., March 1, 2002; 55(3): 162 - 176. [Abstract] [Full Text] [PDF]

				B. Falini and D. Y. Mason Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry Blood, January 15, 2002; 99(2): 409 - 426. [Abstract] [Full Text] [PDF]

				S. WHITTAKER Molecular Genetics of Cutaneous Lymphomas Ann. N.Y. Acad. Sci., September 1, 2001; 941(1): 39 - 45. [Abstract] [Full Text] [PDF]

				H. Stein, H.-D. Foss, H. Durkop, T. Marafioti, G. Delsol, K. Pulford, S. Pileri, and B. Falini CD30+ anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features Blood, December 1, 2000; 96(12): 3681 - 3695. [Abstract] [Full Text] [PDF]

				B. Lawrence, A. Perez-Atayde, M. K. Hibbard, B. P. Rubin, P. Dal Cin, J. L. Pinkus, G. S. Pinkus, S. Xiao, E. S. Yi, C. D. M. Fletcher, et al. TPM3-ALK and TPM4-ALK Oncogenes in Inflammatory Myofibroblastic Tumors Am. J. Pathol., August 1, 2000; 157(2): 377 - 384. [Abstract] [Full Text] [PDF]

				B. Falini, K. Pulford, A. Pucciarini, A. Carbone, C. De Wolf-Peeters, J. Cordell, M. Fizzotti, A. Santucci, P.-G. Pelicci, S. Pileri, et al. Lymphomas Expressing ALK Fusion Protein(s) Other Than NPM-ALK Blood, November 15, 1999; 94(10): 3509 - 3515. [Abstract] [Full Text] [PDF]

				B. Falini, S. Pileri, P. L. Zinzani, A. Carbone, V. Zagonel, C. Wolf-Peeters, G. Verhoef, F. Menestrina, G. Todeschini, M. Paulli, et al. ALK+ Lymphoma: Clinico-Pathological Findings and Outcome Blood, April 15, 1999; 93(8): 2697 - 2706. [Abstract] [Full Text] [PDF]

				J. L. Cordell, K. A.F. Pulford, B. Bigerna, G. Roncador, A. Banham, E. Colombo, P.-G. Pelicci, D. Y. Mason, and B. Falini Detection of Normal and Chimeric Nucleophosmin in Human Cells Blood, January 15, 1999; 93(2): 632 - 642. [Abstract] [Full Text] [PDF]

				I. Wlodarska, C. De Wolf-Peeters, B. Falini, G. Verhoef, S. W. Morris, A. Hagemeijer, and H. Van denBerghe The Cryptic inv(2)(p23q35) Defines a New Molecular Genetic Subtype of ALK-Positive Anaplastic Large-Cell Lymphoma Blood, October 15, 1998; 92(8): 2688 - 2695. [Abstract] [Full Text] [PDF]

				B. Falini, B. Bigerna, M. Fizzotti, K. Pulford, S. A. Pileri, G. Delsol, A. Carbone, M. Paulli, U. Magrini, F. Menestrina, et al. ALK Expression Defines a Distinct Group of T/Null Lymphomas (""ALK Lymphomas"") with a Wide Morphological Spectrum Am. J. Pathol., September 1, 1998; 153(3): 875 - 886. [Abstract] [Full Text] [PDF]

				P. L. Zinzani, M. Martelli, M. Magagnoli, A. Zaccaria, F. Ronconi, M. Cantonetti, M. Bocchia, R. Marra, M. Gobbi, B. Falini, et al. Anaplastic Large Cell Lymphoma Hodgkin's-Like: A Randomized Trial of ABVD Versus MACOP-B With and Without Radiation Therapy Blood, August 1, 1998; 92(3): 790 - 794. [Abstract] [Full Text] [PDF]